These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2474 related items for PubMed ID: 12750613

  • 1. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 2. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K, Mittal BR, Senthil R, Kashyap R, Bhattacharya A, Singh G.
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL, Xue YL, Song HJ, Luo QY.
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [Abstract] [Full Text] [Related]

  • 4. Is (99m)Tc-MDP whole body bone scintigraphy adjuvant to (18)F-FDG-PET for the detection of skeletal metastases?
    Sahin E, Zincirkeser S, Akcan AB, Elboga U.
    J BUON; 2014 Dec; 19(1):291-6. PubMed ID: 24659678
    [Abstract] [Full Text] [Related]

  • 5. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A, Kumar VS, Shamim SA, Gamanagatti S, Khan SA.
    Clin Orthop Relat Res; 2021 Aug 01; 479(8):1768-1779. PubMed ID: 33635285
    [Abstract] [Full Text] [Related]

  • 6. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS, Shahin MA.
    Nucl Med Commun; 2012 Mar 01; 33(3):313-21. PubMed ID: 22237387
    [Abstract] [Full Text] [Related]

  • 7. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
    Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.
    Radiology; 2013 Jun 01; 267(3):891-901. PubMed ID: 23468571
    [Abstract] [Full Text] [Related]

  • 8. Diagnostic performance of 18F-FDG PET/CT and whole-body diffusion-weighted imaging with background body suppression (DWIBS) in detection of lymph node and bone metastases from pediatric neuroblastoma.
    Ishiguchi H, Ito S, Kato K, Sakurai Y, Kawai H, Fujita N, Abe S, Narita A, Nishio N, Muramatsu H, Takahashi Y, Naganawa S.
    Ann Nucl Med; 2018 Jun 01; 32(5):348-362. PubMed ID: 29667143
    [Abstract] [Full Text] [Related]

  • 9. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R, Loening A, Jamali M, Barkhodari A, Mosci C, Jackson T, Obara P, Taviani V, Gambhir SS, Vasanawala S, Iagaru A.
    J Nucl Med; 2015 Dec 01; 56(12):1862-8. PubMed ID: 26405167
    [Abstract] [Full Text] [Related]

  • 10. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M, Pérez-Castejón MJ, Jiménez A, Domper M, Ruiz G, Montz R, Carreras JL.
    Q J Nucl Med; 2002 Jun 01; 46(2):113-21. PubMed ID: 12114874
    [Abstract] [Full Text] [Related]

  • 11. The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques.
    Aukema TS, Rutgers EJ, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MT, Wesseling J, Russell NS, Valdés Olmos RA.
    Eur J Surg Oncol; 2010 Apr 01; 36(4):387-92. PubMed ID: 19962268
    [Abstract] [Full Text] [Related]

  • 12. [Detection of metastases in breast cancer patients: comparison of FDG PET with chest X-ray, bone scintigraphy and ultrasound of the abdomen].
    Dose-Schwarz J, Mahner S, Schirrmacher S, Jenicke L, Müller V, Habermann CR, Brenner W.
    Nuklearmedizin; 2008 Apr 01; 47(3):97-103. PubMed ID: 18493688
    [Abstract] [Full Text] [Related]

  • 13. [The compared study in detecting the recurrence and metastases of breast cancer patients post treatment between (18)F-FDG PET/CT and conventional workup].
    Zhang WG, Wang GH, Zhang WD, Fan W, Li J.
    Zhonghua Yi Xue Za Zhi; 2013 May 21; 93(19):1446-9. PubMed ID: 24029564
    [Abstract] [Full Text] [Related]

  • 14. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS, Urbain JL, Albani JM, Kanvinde MH, Rice TW, Novick AC, Mekhail TM, Olencki TE, Elson P, Bukowski RM.
    J Clin Oncol; 2003 Nov 01; 21(21):3995-4000. PubMed ID: 14581422
    [Abstract] [Full Text] [Related]

  • 15. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
    Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK.
    J Nucl Med; 1998 Mar 01; 39(3):431-5. PubMed ID: 9529287
    [Abstract] [Full Text] [Related]

  • 16. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, Takami M, Kodama K.
    Interact Cardiovasc Thorac Surg; 2010 Jun 01; 10(6):1009-14. PubMed ID: 20197344
    [Abstract] [Full Text] [Related]

  • 17. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW, Jo MK, Lee HM.
    BJU Int; 2009 Mar 01; 103(5):615-9. PubMed ID: 19007371
    [Abstract] [Full Text] [Related]

  • 18. Evaluation of head and neck cancer with 18F-FDG PET: a comparison with conventional methods.
    Kresnik E, Mikosch P, Gallowitsch HJ, Kogler D, Wiesser S, Heinisch M, Unterweger O, Raunik W, Kumnig G, Gomez I, Grünbacher G, Lind P.
    Eur J Nucl Med; 2001 Jul 01; 28(7):816-21. PubMed ID: 11504077
    [Abstract] [Full Text] [Related]

  • 19. Whole-body 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.
    Gajjala SR, Hulikal N, Kadiyala S, Kottu R, Kalawat T.
    Indian J Med Res; 2018 Mar 01; 147(3):256-262. PubMed ID: 29923514
    [Abstract] [Full Text] [Related]

  • 20. (18)F-FDG PET as a single imaging modality in pediatric neuroblastoma: comparison with abdomen CT and bone scintigraphy.
    Choi YJ, Hwang HS, Kim HJ, Jeong YH, Cho A, Lee JH, Yun M, Lee JD, Kang WJ.
    Ann Nucl Med; 2014 May 01; 28(4):304-13. PubMed ID: 24481823
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 124.